Polypeptide Laboratories Inc.

Form 483 issued May 10, 2024 · Torrance, California

Inspection
May 7 – May 10, 2024
Observations
1
Pages
3
FEI number
1000519239

In short: On May 10, 2024, FDA issued a Form 483 with 1 observation to Polypeptide Laboratories Inc. in Torrance, California (FEI 1000519239) after an inspection that ran May 7 – May 10, 2024. The investigators were Andrew Le, Anney Lin, Michael Araneta and Walden H. Lee. Most observations concern facilities & equipment; the most-cited regulation is 21 CFR 211.67 (equipment cleaning and maintenance).

At a glance

1 of 1 observations on this 483 concern facilities & equipment.

Facilities & equipment1

Most cited: 21 CFR 211.67 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Procedures used in the cleaning validation having sensitivity to detect residues or contaminants should be used…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Polypeptide Laboratories Inc.?

FDA listed 1 observation on this Form 483, mostly about facilities & equipment. The most-cited regulation is 21 CFR 211.67 (equipment cleaning and maintenance). The opening words of each observation are shown on this page.

Who inspected Polypeptide Laboratories Inc.?

Andrew Le, Anney Lin, Michael Araneta and Walden H. Lee are named on this Form 483, for the inspection of May 7 – May 10, 2024. Each investigator has a profile showing what they cite most.

When was Polypeptide Laboratories Inc. inspected by FDA?

The inspection ran May 7 – May 10, 2024, and the Form 483 is dated May 10, 2024.

How do I get the full Form 483 for Polypeptide Laboratories Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free
Polypeptide Laboratories Inc. FDA 483 (May 2024) | FDA Intel